Čes. stomatol. Prakt. zub. lék. (Czech Dental Journal) 2013; 113(3): 64-73 | DOI: 10.51479/cspzl.2013.016

An Overview of Recent Possibilities in Pharmacotherapy of Diseases of the Oral Mucosa, Salivary Glands, and Periodontal Tissue

R. Slezák1,*, I. Lindrová1,2, V. Buchta3, V. Paulusová1, Z. Šustová1, O. Kopecký1, L. Ryšková3
1 Stomatologická klinika LF UK a FN, Hradec Králové
2 Ústav klinické imunologie a alergologie LF UK a FN, Hradec Králové
3 Ústav klinické mikrobiologie LF UK a FN, Hradec Králové

Introduction: A review of newer drugs for topical or systemic administration useful in contemporary dentistry in the therapy of diseases of periodontal tissue, oral mucous membrane, and salivary glands available in Czech Republic was given in this article.

Objectives: There were discussed mouthrinses containing chlorhexidine in lower concentrations and/or oxidation agents associated with reduced dark discoloration of teeth and lingual mucosa. FotoSan 630 represents a system for photodynamic antimicrobial therapy using monochromatic light produced by light-emitting diods for the photoinitiation of the toluidine blue O as a photosensitizer. It is declared for the supportive topical treatment of plaque-induced periodontopathies, periimplant defects, dry socket, infected root canals and caries lesions. Hyaluronic acid contained in commercial gel products Aloclair and Gengigel, lubricative product Aequasyal, and gel product SineHerp are recommended in topical treatment of various less serious diseases of the oral mucosa and salivary glands. Drugs for systemic administration discussed here are antileukotriene immunomodulator montelucast, immunosuppressive and antiinflammatory drugs thalidomide and leflunomid. They are usable in the therapy of more serious mucosal diseases, mostly of autoimmune or uncertain origin. Caspofungin, micafungin and anidulafungin are modern echinocandin antimycotics for parenteral use indicated for treatment of severe mycotic infections, mostly candidiasis in altered individuals. Drugs for biological therapy declared as antitumorous and antiinflammatory agents already seldom used in dentistry are monoclonal antibodies rituximab, cetuximab, and erlotinib, potentially useful are also etanercept, infliximab and adalimumab. Botulotoxin is a neurotoxin of bacterial origin used at present in the therapy of various neurological disturbances in the head and neck area.

Keywords: periodontal tissue; oral mucous membrane; salivary glands; chlorhexidine; photodynamic antimicrobial therapy; hyaluronic acid; montelucast; thalidomide; leflunomide; echinocandins; biological therapy; botulotoxin

Published: September 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slezák R, Lindrová I, Buchta V, Paulusová V, Šustová Z, Kopecký O, Ryšková L. An Overview of Recent Possibilities in Pharmacotherapy of Diseases of the Oral Mucosa, Salivary Glands, and Periodontal Tissue. Čes. stomatol. Prakt. zub. lék. 2013;113(3):64-73. doi: 10.51479/cspzl.2013.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allen, D. R., Davies, R., Bradshaw, B., Ellwood, R., Simone, A. J., Robinson, R., Mukerjee, C., Petrone, M. E., Chaknis, P., Volpe, A. R., Proskin, H. M.: Efficacy of a mouthrinse containing 0.05% cetylpyridinium chloride for the control of plaque and gingivitis: a 6-month clinical study in adults. Compend. Contin. Educ. Dent., roč. 19, 1998, Suppl. 2, s. 20-26.
    2. Aloclair. http://www.sinclairispharma.com
    3. Bečvář, R., Vencovský, J., Němec, P., Suchý, D., Procházková, L., Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Účinnost a strategie léčby. Čes. Revmatol., roč. 15, 2007, č. 2, s. 16-32.
    4. Blitzer, A., Benson, B. E., Guss, J.: Botulinum neurotoxin for head and neck disorders, 1. vyd. Thieme, New York Stuttgart, 2012. Go to original source...
    5. Compilato, D., Colella, G., Fulfaro, F., Vicidomini, A., Campisi, G.: Effective use of sodium-hyaluronate spray formulation in oral mucositis. Oral Dis., roč. 18, 2012, Suppl. 1, s. 25.
    6. Denning, D. W.: Echinocandin antifungal drugs. Lancet, roč. 362, 2003, s. 1142-1151. Go to original source... Go to PubMed...
    7. EPOC. http://clinicaltrials.gov/show/NCT00402779 Erlotinib Prevention of Oral Cancer (EPOC).
    8. Fusek, M., Vítek, L., Blahoš, J., Jr., Hajdúch, M., Ruml, T., a kol.: Biologická léčiva. Teoretické základy a klinická praxe, 1. vyd. Grada Publishing, a. s., Praha, 2012.
    9. Gengigel http://www.ricerfarma.com
    10. Hello, M., Barbarot, S., Bastuji-Garin, S., Revuz, J., Chosidow, O.: Use of thalidomide for severe recurrent aphthous stomatitis: A multicenter cohort analysis. Medicine (Baltimore), roč. 89, 2010, č. 3, s. 176-182. Go to original source... Go to PubMed...
    11. Hodgson, T. A.: Adverse drug reactions: What is new? Oral Dis., roč. 18, 2012, Suppl. 1, s. 2.
    12. Chrysomali, E., McCullough, M.: Updates of diagnostic and therapeutic dilemmas in oral medicine. Management of recurrent aphthous ulcers: What's new? Oral Dis., roč. 18, 2012, Suppl. 1, s. 2.
    13. Johannsen, A., Tellefsen, M., Wilkesjø, U., Johannsen, G.: Local delivery of hyaluronan as an adjunct to scaling and root planning in the treatment of chronic periodontitis. J. Periodontol., roč. 80, 2009, č. 9, s. 1492-1497. Go to original source... Go to PubMed...
    14. Konopka, K., Goslinski, T.: Photodynamic therapy in dentistry. J. dent. Res., roč. 86, 2007, č. 8, s. 694-707. Go to original source... Go to PubMed...
    15. Krejsek, J., Kopecký, O.: Modulace imunitního systému (kap.) In: Krejsek, J., Kopecký, O.: Klinická imunologie. Hradec Králové, Praha, Nucleus HK, 2004, 1. vyd., s. 804-810.
    16. Mariette, X.: How does BAFF activate B cells in patients with autoimmune diseases? Arthritis Res. Therap., roč. 14, 2012, č. 1, s. 106. doi: 10.1186/ar3729 Go to original source... Go to PubMed...
    17. Martín-Piedra, M. A., Aguilar-Salvatierra, A., Herrera, D., Gómez-Moreno, G.: Effectiveness of a recent topical sialogogue in the management of drug-induced xerostomia. J. Clin. Exp. Dent., roč. 3, 2011, č. 4, s. e268-273. Go to original source...
    18. McParland, H., Escudier, M., Mills, R., Cook, R. J., Kovacevic, T., Challacombe, S. J., Shirlaw, P. J.: Thalidomide for recalcitrant recurrent oral ulcerations: 20 years experience. Oral Dis., roč. 18, 2012, Suppl. 1, s. 27.
    19. Meijer, J. M., Meiners, P. M., Vissink, A.: Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum., roč. 62, 2010, č. 4, s. 960-968. Go to original source... Go to PubMed...
    20. Mouly, S., Salom, M., Tillet, Y., Coudert, A.-C., Oberli, F., Preshaw, P. M., Desjonquères, S., Bergmann, J.-F.: Management of xerostomia in older patients: A randomised controlled trial evaluating the efficacy of a new oral lubricant solution. Drugs Aging, roč. 24, 2007, č. 11, s. 957-965. Go to original source... Go to PubMed...
    21. Opstelten, W., Neven, A. K., Eekhof, J.: Treatment and prevention of herpes labialis. Canad. Fam. Phys., roč. 54, 2008, s. 1683-1687.
    22. Pála, M.: Současná úloha chemoterapie a cílené biologické léčby v kurativní a paliativní léčbě spinocelulárního karcinomu hlavy a krku. Onkologie, roč. 6, 2012, č. 5, s. 257-259.
    23. Pavelka K., Vencovský, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Čes. Revmatol., roč. 18, 2010, č. 4, s. 182-191.
    24. Pijpe, J., van Imhoff, G. W., Spijkervet, F. K., Roodenburg, J. L., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G., Bootsma, H.: Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum., roč. 52, 2005, č. 9, s. 2740-2750. Go to original source... Go to PubMed...
    25. Prolia®. Prolia product manager. Amgen Canada Inc., 2012.
    26. Ryskova, L., Buchta, V., Slezak, R.: Photodynamic antimicrobial therapy. Centr. Eur. J. Biol., roč. 5, 2010, č. 4, s. 400-406. Go to original source...
    27. Saji, G., Kisen, A.: Advanced noninvasive light-activate disinfection: Assessment of cytotoxicity on fibroblast versus antimicrobial activity against Enterococcus faecalis. J. Endod., roč. 33, 2007, č. 5, s. 599-602. Go to original source... Go to PubMed...
    28. Sapna, N, Vandana, K. L.: Evaluation of hyaluronan gel (Gengigel®) as a topical applicant in the treatment of gingivitis. J. Invest. Clin. Dent., roč. 2, 2011, č. 3, s. 162-170. Go to original source... Go to PubMed...
    29. Shetty, K.: Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: A review and case reports. Spec. Care Dent., roč. 25, 2005, č. 5, s. 236-241. Go to original source... Go to PubMed...
    30. Schlafer, S., Vaeth, M., Hørsted-Bindslev, P., Frandsen, E. V. G.: Endodontic photoactivated disinfection using a conventional light source: An in vitro and ex vivo study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 109, 2010, s. 634-641. Go to original source... Go to PubMed...
    31. Sigush, B. W., Pfitzner, A., Albrecht, V., Glockmann, E.: Efficacy of photodynamic therapy on inflammatory signs and two selected periodontopathogenic species in a beagle dog model. J. Periodontol., roč. 76, 2005, s. 1100-1005. Go to original source... Go to PubMed...
    32. Slezák, R., Šustová, Z., Nováková, V.: Pokroky ve farmakoterapii chorob ústní sliznice. Čes. Stomat., roč. 109, 2009, č. 1, s. 7-14.
    33. Slezák, R., Ryšková, L., Paulusová, V., Šustová, Z., Berglová, I., Buchta, V.: Nové možnosti ve farmakoterapii chorob parodontu a ústní sliznice. Čes. Stomat., roč. 112, 2012, č. 1, s. 15-22. Go to original source...
    34. Sreenivasan, P. K., Haraszthy, V. I., Zambon, J. J.: Antimicrobial efficacy of 0.05% cetylpyridinium chloride mouthrinses. Lett. Applic. Microbiol., 2012, Oct 8., doi: 10.1111/lam.12008. [Epub ahead of print]. Go to original source... Go to PubMed...
    35. Sukumar, S., Dřízhal. I.: Hyaluronic acid and periodontitis. Acta Medica (Hradec Králové), roč. 50, 2007, č. 4, s. 225-228. Go to original source...
    36. Yagiela, J. A., Dowd, F. J., Johnson, B. S., Mariotti, A. J., Neidle, E. A.: Pharmacology of specific drug groups (part II), Special subjects in pharmacology and therapeutics (part III). In: Yagiela, J. A., Dowd, F. J., Johnson, B. S., Mariotti, A. J., Neidle, E. A.: Pharmacology and therapeutics for dentistry. Mosby Elsevier, 2011, 6. vyd., s. 78-744, s. 752-867.
    37. Zakka, L. R., Shetty, S. S., Ahmed, A. R.: Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb.) roč. 2, 2012, č. 1. Epub 2012 Nov 15. Dostupné z: www.ncbi.nlm.nih.gov/pubmed/23205339. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content